Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy.

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia & Lymphoma Pub Date : 2025-06-23 DOI:10.1080/10428194.2025.2502805

John Kuruvilla, Dipenkumar Modi, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, Laura Maria Fogliatto, Iara Gonçalves, Jose de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Iryna Kriachok, Naohiro Sekiguchi, Jianxin Lin, Rushdia Yusuf, Patricia Marinello, Pier Luigi Zinzani

{"title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy.","authors":"John Kuruvilla, Dipenkumar Modi, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, Laura Maria Fogliatto, Iara Gonçalves, Jose de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Iryna Kriachok, Naohiro Sekiguchi, Jianxin Lin, Rushdia Yusuf, Patricia Marinello, Pier Luigi Zinzani","doi":"10.1080/10428194.2025.2502805","DOIUrl":null,"url":null,"abstract":"This report focuses on a post hoc exploratory analysis of the phase 3 keynote-204 study comparing pembrolizumab and brentuximab vedotin by number of prior lines of therapy in participants with relapsed/refractory (r/r) classical hodgkin lymphoma (chl). of 304 participants randomly assigned (1: 1) to pembrolizumab or brentuximab vedotin, 55 received 1 prior therapy and 249 received ≥2. For 1 prior therapy, median progression-free survival (PFS) at primary analysis (including clinical imaging data after autologous stem cell transplant [auto-SCT]) was 16.4 months with pembrolizumab and 8.4 months with brentuximab vedotin; objective response rate (ORR) was 66.7% and 53.6%. For ≥2 prior therapies, median PFS at primary analysis was 12.6 months with pembrolizumab and 8.2 months with brentuximab vedotin; ORR was 65.3% and 54.4%. Pembrolizumab improved PFS and ORR versus brentuximab vedotin regardless of prior therapies. Data suggest pembrolizumab may be a promising second-line therapy for participants with R/R cHL ineligible for auto-SCT.Clinical trial information: ClinicalTrials.gov, NCT02684292.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2502805","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This report focuses on a post hoc exploratory analysis of the phase 3 keynote-204 study comparing pembrolizumab and brentuximab vedotin by number of prior lines of therapy in participants with relapsed/refractory (r/r) classical hodgkin lymphoma (chl). of 304 participants randomly assigned (1: 1) to pembrolizumab or brentuximab vedotin, 55 received 1 prior therapy and 249 received ≥2. For 1 prior therapy, median progression-free survival (PFS) at primary analysis (including clinical imaging data after autologous stem cell transplant [auto-SCT]) was 16.4 months with pembrolizumab and 8.4 months with brentuximab vedotin; objective response rate (ORR) was 66.7% and 53.6%. For ≥2 prior therapies, median PFS at primary analysis was 12.6 months with pembrolizumab and 8.2 months with brentuximab vedotin; ORR was 65.3% and 54.4%. Pembrolizumab improved PFS and ORR versus brentuximab vedotin regardless of prior therapies. Data suggest pembrolizumab may be a promising second-line therapy for participants with R/R cHL ineligible for auto-SCT.

Clinical trial information: ClinicalTrials.gov, NCT02684292.

查看原文本刊更多论文

Pembrolizumab治疗复发或难治性霍奇金淋巴瘤：KEYNOTE-204的事后分析

本报告的重点是对3期keynote-204研究的回顾性探索性分析，比较了pembrolizumab和brentuximab vedotin在复发/难治性（r/r）经典霍奇金淋巴瘤（chl）患者的既往治疗线数量。在304名参与者中，随机分配（1:1）到派姆单抗或布伦妥昔单抗韦多汀组，55名接受了1次治疗，249名接受了≥2次治疗。对于1次既往治疗，初步分析（包括自体干细胞移植[auto-SCT]后的临床影像学数据）的中位无进展生存期（PFS）为派姆单抗16.4个月，布伦妥昔单抗为8.4个月；客观有效率（ORR）分别为66.7%和53.6%。对于既往治疗≥2次的患者，初步分析时pembrolizumab组的中位PFS为12.6个月，brentuximab vedotin组为8.2个月；ORR分别为65.3%和54.4%。与brentuximab vedotin相比，Pembrolizumab改善了PFS和ORR，无论先前的治疗如何。数据显示，派姆单抗可能是一种有希望的二线治疗，用于不适合进行自体细胞移植的R/R cHL患者。临床试验信息：ClinicalTrials.gov, NCT02684292。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia & Lymphoma 医学-血液学

CiteScore

4.10

自引率

3.80%

发文量

384

审稿时长

1.8 months

期刊介绍： Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor